Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab + Lenvatinib with TACE in HCC
NCT06371157Phase 3Recruiting
- Sponsor
- Akeso, Inc.
- Start
- Aug 2024
- Primary completion
- Oct 2025
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of cadonilimab in hepatocellular carcinoma (HCC) (3 arms), sponsored by Akeso, Inc. Primary endpoint: Progression-Free Survival up to 2 years. Started Aug 2024; status: recruiting.
02
Drugs
cadonilimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06371157.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06371157.